Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks ...

Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...

and exit the consumer health market as it moves towards a target of generating €10 billion in annual sales from new products by the end of the decade. Sanofi said it expects the deal to close in ...

costly patent expirations of top-selling products as are some rivals. "We've spent five years as a team getting Sanofi to the start line of being a respected R&D machine, and I think the markets ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

Analysts at Zacks Research decreased their Q4 2025 earnings estimates for Sanofi in a research note issued on Tuesday, ...

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for ...

Recordati said its milestone payment to Sanofi is tied to the achievement of net sales at or above the top end of peak year ... complementary to one of those products, Sylvant.

Sanofi today announces that the company has entered into negotiations ... Headquartered in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 best-in-class ...

Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring ... wrote in similar ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholderWith 11,000 talented and passionate people bringing iconic ...